The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705
Open accessAbstract
T-705 (6-fluoro-3-hydroxy-2-pyrazinecarboxamide) has been found to have potent and selective inhibitory activity against influenza virus. In an in vitro plaque reduction assay, T-705 showed potent inhibitory activity against influenza A, B, and C viruses, with 50% inhibitory concentrations (IC 50 s) of 0.013 to 0.48 μg/ml, while it showed no cytotoxicity at concentrations up to 1,000 μg/ml in Madin-Darby canine kidney cells. The selectivity index for influenza virus was more than 2,000. It was also active against a neuraminidase inhibitor-resistant virus and some amantadine-resistant viruses. T-705 showed weak activity against non-influenza virus RNA viruses, with the IC 50 s being higher for non-influenza virus RNA viruses than for influenza virus, and it had no activity against DNA viruses. Orally administered T-705 at 100 mg/kg of body weight/day (four times a day) for 5 days significantly reduced the mean pulmonary virus yields and the rate of mortality in mice infected with influenza virus A/PR/8/34 (3 × 10 2 PFU). These results suggest that T-705 may be a compound that is useful and highly selective against influenza virus infections and that has a mode of action different from those of commercially available drugs, such as amantadine, rimantadine, and neuraminidase inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rational design of potent sialidase-based inhibitors of influenza virus replication
von Itzstein, M., Wu, W.-Y., Kok, G. B., Pegg, M. S., Dyason, J. C., Jin, B., Van Phan, T., Smythe, M. L., White, H. F., Oliver, S. W., et al. (1993) · Nature · doi:10.1038/363418a0 · Cited by 1,862
Hayden, F. G., Osterhaus, A. D. M. E., Treanor, J. J., Fleming, D. M., Aoki, F. Y., Nicholson, K. G., Bohnen, A. M., Hirst, H. M., Keene, O., & Wightman, K. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709253371302 · Cited by 762
A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection
Dolin, R., Reichman, R. C., Madore, H. P., Maynard, R., Linton, P. N., & Webber-Jones, J. (1982) · New England Journal of Medicine · doi:10.1056/nejm198209023071002 · Cited by 501
Research works printed but not linked: 27
- 10.1038/82191 · DOI · Paper page
- Eggleston, M. 1987. Clinical review of ribavirin. Infect. Control8:215-218. · DOI
- 10.1128/AAC.11.6.946 · DOI · Paper page
- 10.1128/jb.92.6.1710-1715.1966 · DOI
- 10.1093/oxfordjournals.epirev.a036250 · DOI · Paper page
- 10.1016/0006-291X(79)91853-9 · DOI · Paper page
- 10.1002/jmv.1890260207 · DOI · Paper page
- 10.1128/AAC.17.5.865 · DOI · Paper page
- 10.1056/NEJM198912213212502 · DOI · Paper page
- 10.1128/AAC.35.9.1741 · DOI
- Hui, M. B. V., E. J. Lien, and M. D. Trousdale. 1994. Inhibition of human adenoviruses by 1-(2′-hydroxy-5′-methoxybenzylidene)amino-3-hydroxyguanidine tosylate. Antivir. Res.24:261-273. · doi:10.1016/0166-3542(94)90074-4
- Kim, C. U., W. Lew, M. A. Williams, H. Wu, L. Zhang, X. Chen, P. A. Escarpe, D. B. Mendel, W. G. Laver, and R. C. Stevens. 1998. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. J. Med. Chem.41:2451-2460. · DOI · Paper page
- Kurokawa, M., H. Ochiai, K Nagasaka, M. Neki, H. Xu, S. Kadota, S. Sutardjo, T Matsumoto, T Namba, and K. Shiraki. 1993. Antiviral traditional medicines against herpes simplex virus (HSV-1), poliovirus and measles virus in vitro and their therapeutic efficacies for HSV-1 infection in mice. Antivir. Res.22:175-188. · doi:10.1016/0166-3542(93)90094-y
- 10.1128/AAC.44.4.859-866.2000 · doi:10.1128/aac.44.4.859-866.2000
- 10.1128/AAC.42.3.640 · DOI · Paper page
- 10.1016/S0140-6736(00)02288-1 · DOI · Paper page
- Perrotta, D. M., M. Decker, and W. P. Glezen. 1985. Acute respiratory disease hospitalizations as a measure of impact of epidemic influenza. Am. J. Epidemiol.122:468-476. · DOI
- 10.1016/0092-8674(92)90452-I · DOI · Paper page
- Scudiero, D. A., R. H. Shoemaker, K. D. Paull, A. Monks, S. Tierney, T. H. Nofziger, M. J.Currens, D. Seniff, and M. R. Boyd. 1988. Evaluation of a tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res.48:4827-4833.
- 10.1126/science.177.4050.705 · DOI · Paper page
- 10.1073/pnas.70.4.1174 · DOI · Paper page
- 10.1128/AAC.42.12.3234 · DOI
- 10.1001/jama.283.8.1016 · DOI · Paper page
- U.S. Food and Drug Administration. 1986. Ribavirin aerosol approved for severe cases of RSV in infants and young children. FDA Drug Bull.16:7.
- 10.1128/jvi.67.9.5585-5594.1993 · DOI · Paper page
- Witkowski, J. T., R. K. Robins, R. W. Sidwell, and L. N. Simon. 1972. Design, synthesis, and broad spectrum antiviral activity of 1-β-d-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides. J. Med. Chem.15:1150-1154. · DOI · Paper page
- Yukawa, T. A., M. Kurokawa, H. Sato, Y. Yoshida, S. Kageyama, T. Hasegawa, T. Namba, M. Imakita, T. Hozumi, and K. Shiraki. 1996. Prophylactic treatment of cytomegalovirus infection with traditional herbs. Antivir. Res.32:63-70. · doi:10.1016/0166-3542(95)00978-7
Cited by
Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial
Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., et al. (2020) · doi:10.1101/2020.03.17.20037432 · Cited by 852
Antiviral agents active against influenza A viruses
De Clercq, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2175 · Cited by 668
Sissoko, D., Laouenan, C., Folkesson, E., M’Lebing, A.-B., Beavogui, A.-H., Baize, S., Camara, A.-M., Maes, P., Shepherd, S., Danel, C., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001967 · Cited by 478
The mechanism of resistance to favipiravir in influenza
Goldhill, D. H., te Velthuis, A. J. W., Fletcher, R. A., Langat, P., Zambon, M., Lackenby, A., & Barclay, W. S. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811345115 · Cited by 298
Pizzorno, A., Padey, B., Terrier, O., & Rosa-Calatrava, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00531 · Cited by 122
Metadata
- Authors
- Furuta, Y., Takahashi, K., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., Nomura, N., Egawa, H., Minami, S., Watanabe, Y., Narita, H., & Shiraki, K.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2002-04
- Volume
- 46
- Issue
- 4
- Pages
- 977-981
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2108367829
- Cited by
- 501
- References
- 3
- FWCI
- 1.90
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705. https://app.cochat.ai/papers/10.1128/aac.46.4.977-981.2002
- The paper
- Furuta, Y., Takahashi, K., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., Nomura, N., Egawa, H., Minami, S., Watanabe, Y., Narita, H., & Shiraki, K. (2002). In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.46.4.977-981.2002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
